A Phase 1, Open-label Study to Evaluate the Biodistribution and Safety of 18F-LY3950321 (18F-MNI-1256) in Healthy Subjects
Latest Information Update: 28 Mar 2023
At a glance
- Drugs 18 LY3950321 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Avid Radiopharmaceuticals
Most Recent Events
- 24 Mar 2023 New trial record